Normal function · from ai-gene-review (O00170, commit 79fe13b38970) · AI-generated, not KB evidence

AIP (AH receptor-interacting protein, also known as XAP2/ARA9) is a ~37 kDa, 330-amino acid FKBP-type immunophilin homolog that functions primarily as a non-enzymatic co-chaperone/scaffold in the HSP90-AHR (aryl hydrocarbon receptor) cytosolic complex. It contains an N-terminal FKBP-type PPIase-like domain that is catalytically inactive (lacking PPIase enzymatic activity and FK506/rapamycin binding) and C-terminal TPR repeats (three TPR motifs plus a terminal alpha-7 helix) that mediate interactions with HSP90 and TOMM20. Cryo-EM structural analysis of the human agonist-bound AHR cytosolic complex (DOI:10.1038/s41467-022-34773-w) reveals AIP/XAP2 acting as a structural brace associated with the HSP90 dimer and the AHR client, with the HSP90 C-terminal MEEVD motif docked into the TPR domain of AIP. AIP has also been reported to facilitate TOMM20-dependent mitochondrial preprotein import and to suppress thermal aggregation of model substrates in vitro, consistent with a holdase-like assay result in this import context rather than a broad protein-folding chaperone role. Beyond the AHR complex, AIP also interacts with phosphodiesterases PDE4A5 and PDE2A3, linking it to localized cAMP regulation and modulation of AHR nuclear translocation. Proteomic studies show AIP co-localizes with HSPA9 in the mitochondrial chaperone network, consistent with mitochondrial chaperone-network association (DOI:10.18632/oncotarget.24183). Germline loss-of-function AIP variants predispose to pituitary neuroendocrine tumors (PitNETs) with incomplete penetrance (~12-30%), behaving as a tumor suppressor with a two-hit model (loss of heterozygosity in tumors). AIP mutations account for ~29% of childhood-onset GH-secreting pituitary tumors presenting as gigantism and ~9% of macroprolactinomas presenting before age 20 (DOI:10.1038/s41574-023-00948-8).

AIP/XAP2 binds HSP90 via its C-terminal TPR domain (three TPR motifs plus a terminal alpha-7 helix), serving as a co-chaperone/scaffold in the AHR-HSP90 complex. The TPR domain engages the MEEVD motif at the HSP90 C-terminus (PDB:4APO). Cryo-EM structure of the human agonist-bound HSP90-XAP2-AHR cytosolic complex (DOI:10.1038/s41467-022-34773-w) reveals AIP acting as a structural brace associated with the HSP90 dimer and the AHR client, with the MEEVD motif docked into the TPR domain of AIP, consistent with canonical TPR-mediated recruitment of HSP90 co-chaperones. Disease-causing mutations in the TPR domain disrupt HSP90 binding and are associated with pituitary neuroendocrine tumor predisposition (PitNET/PITA1), consistent with a two-hit tumor suppressor model (loss of heterozygosity in tumors).
molecular function: Hsp90 protein binding · locations: cytosol · in complex: aryl hydrocarbon receptor complex
AIP/XAP2 is a stoichiometric component of the unliganded AHR 9S core complex (AHR:2xHSP90:AIP:PTGES3), binding directly to the aryl hydrocarbon receptor. It stabilizes the cytosolic AHR-HSP90 complex, enhancing AhR receptivity for ligand and subsequent transcriptional activation. Cryo-EM structural analysis (DOI:10.1038/s41467-022-34773-w) confirms the architectural arrangement of AIP as a brace spanning the HSP90 dimer and AHR client within this complex.
molecular function: aryl hydrocarbon receptor binding · locations: cytosol · in complex: aryl hydrocarbon receptor complex
AIP binds to the GAF-B domain of phosphodiesterase 2A (PDE2A), an interaction that inhibits TCDD- and cAMP-induced nuclear translocation of AhR in hepatocytes, providing a regulatory link between cAMP signaling and the AhR pathway. AIP also interacts with PDE4A5, further linking it to localized cAMP regulation (DOI:10.1586/eem.10.42). These phosphodiesterase interactions suggest AIP may modulate pituitary tumor biology through cAMP pathway effects.
molecular function: GAF domain binding · locations: cytosol
In the knowledge base · computed from kb/ at build time

Disorders

Relationship is the entry's genetic[].relationship_type. untyped means the entry has a genetic record for the gene but does not type it; its free-text association is shown instead.

DisorderRelationshipWhere the gene appears
AIP-related pituitary adenoma predisposition susceptibility germlinegermline and somaticsomatic loss of function
mechanism: Altered ligand-dependent growth hormone secretion; Biallelic AIP-deficient somatotroph state; Disrupted AIP-dependent PDE4A cAMP-phosphodiesterase module; Germline AIP loss-of-function predisposition; Reduced AIP-AHR co-chaperone binding function; Somatic second-hit AIP inactivation
diagnosis: AIP molecular genetic testing
Pituitary Tumor no genetic record
mechanism: Clonal Expansion of an Adenohypophyseal Cell Lineage
subtype: Somatotroph

Identity from HGNC (snapshot 2026-10-01). Page layers are described in the gene pages documentation.